![](/img/cover-not-exists.png)
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study
Kiladjian, Jean-Jacques, Zachee, Pierre, Hino, Masayuki, Pane, Fabrizio, Masszi, Tamas, Harrison, Claire N, Mesa, Ruben, Miller, Carole B, Passamonti, Francesco, Durrant, Simon, Griesshammer, Martin,Language:
english
Journal:
The Lancet Haematology
DOI:
10.1016/S2352-3026(19)30207-8
Date:
January, 2020
File:
PDF, 1.29 MB
english, 2020